{
  "id": "9c0ae23b5ded197b",
  "title": "Medicaid Tries New Approach With Sickle Cell : Companies Get Paid Only if Costly Gene Therapies Work",
  "description": "20260121T121500Z",
  "content": "",
  "source": "kffhealthnews.org",
  "source_url": "https://kffhealthnews.org/news/article/sickle-cell-disease-gene-therapy-medicaid-vertex-bluebird-bio/",
  "published_at": "20260121T121500Z",
  "fetched_at": "2026-01-22T00:25:11.997161+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [
    "ai"
  ],
  "location": "",
  "raw_data": {
    "url": "https://kffhealthnews.org/news/article/sickle-cell-disease-gene-therapy-medicaid-vertex-bluebird-bio/",
    "url_mobile": "https://kffhealthnews.org/news/article/sickle-cell-disease-gene-therapy-medicaid-vertex-bluebird-bio/amp/",
    "title": "Medicaid Tries New Approach With Sickle Cell : Companies Get Paid Only if Costly Gene Therapies Work",
    "seendate": "20260121T121500Z",
    "socialimage": "https://kffhealthnews.org/wp-content/uploads/sites/2/2026/01/Sickle-cell-drugs-05-lo.jpg",
    "domain": "kffhealthnews.org",
    "language": "English",
    "sourcecountry": ""
  }
}